$ILMN

Davies Scott M sold $98K of ILMN

Davies Scott M (Chief Legal Officer) sold 615 shares of ILLUMINA, INC. (ILMN) at $160.00 on 2026-05-29 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Davies Scott M
Published Jun 1, 2026, 4:00 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 6, 2026, 8:58 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$ILMN
Neutral
high confidence
Mentioned
$ILMN
Relevance
2/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$ILMNNeutralLow
01

Why it matters

The newest fact is the officer’s open-market sale details (615 shares at $160) and that it was executed under a pre-arranged Rule 10b5-1 plan.

02

Market read

Traders may note the insider sale, but the 10b5-1 structure and modest transaction size reduce expected market impact.

03

What to watch

The article provides no context on whether this sale is part of a larger series, nor any concurrent company-specific news, limiting inference beyond the transaction itself.

Relevance 2/10Novelty 3/10Timing: filed June 1, transaction dated May 29

Background

The article is a SEC Form 4 insider transaction disclosure for Illumina, Inc. (ILMN).

Company-level read

Ticker impact

$ILMNNeutralHigh confidence
Context

Illumina disclosed a Form 4 showing Chief Legal Officer Davies Scott M sold 615 shares at $160 on May 29 under a 10b5-1 plan.

Expected impact

Low likelihood of a sustained price move from this filing alone; any reaction is likely muted.

Evidence & confidence

The filing is an open-market sale by an officer, explicitly tied to a pre-arranged 10b5-1 plan, and the disclosed size is modest relative to typical large-cap trading flows.

Market effects

No clear read-through to the biotech tools or sequencing equipment sector from a single routine 10b5-1 sale.

None indicated.

None indicated.

Counterpoint

Even with a 10b5-1 plan, repeated insider selling can coincide with internal caution, so traders may still watch for follow-on sales or other negative disclosures.

Key entities

  • Illumina, Inc.

    Subject of the Form 4 insider transaction disclosure.

  • Davies Scott M

    Chief Legal Officer who sold shares under a 10b5-1 plan.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$ILMNHighAI 8/10

Illumina Q2FY26 Results: Revenue up 9.5% to $1.16 billion

Illumina reported Q2 2026 revenue of $1.16B, up 9.5% YoY, driven by NovaSeq X demand and clinical consumables growth. Non-GAAP EPS rose 10% to $1.31. The company raised full-year guidance, projecting revenue of $4.60B-$4.64B and EPS of $5.30-$5.40. Management cited strong instrument placements and cost management despite rising expenses. Illumina repurchased 0.9M shares and holds $1.17B in cash. The stock has returned 13.26% annually over 20 years, outperforming the market by 3.84%.

$ILMNHighAI 8/10

Illumina Reports Q2 2026 Results: Full Earnings Call Transcript - Illumina (NASDAQ:ILMN)

Illumina (ILMN) reported Q2 2026 revenue growth of 9.5% YoY and EPS growth of 10%, driven by strong demand for NovaSeq X. The company raised its 2026 guidance, expecting full-year organic revenue growth over 5% and mid-teens growth in clinical consumables. Strategic initiatives include expanding multi-omics capabilities and strengthening the BioInsight platform. Management emphasized cost management and confidence in long-term targets.

$BELow

Three Stocks Are Joining the S&P 500. Will They Actually Improve VOO’s Returns?

Vanguard S&P 500 ETF (VOO) will add Bloom Energy (BE), Illumina (ILMN), and another company, while removing Molson Coors (TAP), The Trade Desk (TTD), and Builders FirstSource (BLDR). BE's product revenue surged 215% due to AI demand, and ILMN raised EPS guidance. The changes have minimal impact on VOO's returns, as the fund is heavily concentrated in megacap stocks.

$ILMNHigh

Illumina Stock Climbs As Analyst Upgrades Meet S&P 500 Boost

Illumina Inc. (ILMN) shares rose 7.15% on September 15, 2026, after UBS upgraded it to Buy with a $260 price target, and Argus raised its target to $235. The company's Q2 revenue was $1.16B, with EBITDA of $354M. Illumina is also being added to the S&P 500, effective September 21, 2026, which may drive further demand. The stock trades at a P/E ratio of 38 and P/S ratio of 6.9, reflecting its growth prospects. Analysts cite revenue reacceleration, margin expansion, and clinical demand as key driv